Vol.

No.

July 30, 2015Jul 30, 2015

Free

DOWNLOAD THE PDF

Pharma Industry Critics Seek Grassroots Support

Cover Story

Free

Pharma Industry Critics Seek Grassroots Support

By Paul Goldberg

Many people are studying the rising prices of cancer drugs. A growing group of oncologists want to do something different: they want to give them a downward push.

Conversation with The Cancer Letter Free

The War on Cancer (Drug Prices): Political Education of Hagop Kantarjian

By Paul Goldberg

Free

Baylor Earns Comprehensive Designation; Tisch Institute Becomes NCI Cancer Center

By Matthew Bin Han Ong

Free Guest Editorial

Kids v Cancer: Laws Need to Catch up to the Science

By Nancy Goodman

In Brief

Schulam to Serve as Interim Director of Yale Cancer Center as Lynch Plans to Step Down

Peter Schulam to serve as interim center director

Karen Reckamp named medical director for clinical research at City of Hope

Timothy Lash named leader of cancer prevention program at Winship Institute

Ontario Institute for Cancer Research and Centre for Drug Research and Development announces call for pre-proposals for early-stage research

Drugs & Targets

Lenvima Receives Breakthrough Therapy Designation from FDA

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 51 | Issue 46 - December 19, 2025

Pharma Industry Critics Seek Grassroots Support

The War on Cancer (Drug Prices): Political Education of Hagop Kantarjian

Baylor Earns Comprehensive Designation; Tisch Institute Becomes NCI Cancer Center

Kids v Cancer: Laws Need to Catch up to the Science

In Brief

Schulam to Serve as Interim Director of Yale Cancer Center as Lynch Plans to Step Down

Peter Schulam to serve as interim center director

Karen Reckamp named medical director for clinical research at City of Hope

Timothy Lash named leader of cancer prevention program at Winship Institute

Ontario Institute for Cancer Research and Centre for Drug Research and Development announces call for pre-proposals for early-stage research

Drugs & Targets

Lenvima Receives Breakthrough Therapy Designation from FDA

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login